Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. In 14 healthy subjects, administration of a single 125 mg dose of palbociclib with multiple 400 mg daily doses of modafinil, a moderate CYP450 3A4 inducer, resulted in 11% and 32% decreases in palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC), respectively, compared to palbociclib administered alone.

MANAGEMENT: The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.

Palbociclib oral capsules (Ibrance) should be taken with food to help with its absorption. Palbociclib oral tablets (Ibrance) may be taken with or without food. Do not consume grapefruit or grapefruit juice during treatment with palbociclib. Grapefruit and grapefruit juice can interact with palbociclib and increase the levels of palbociclib in your body. You may be more likely to experience side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; hair loss; weakness; pain, numbness, or tingling in the hands and feet; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.